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Background: The significance of nontuberculous mycobacteria (NTM) isolated from a patient
during therapy for pulmonary tuberculosis (TB) is uncertain. We investigated the frequency
and clinical significance of NTM isolated from patients receiving anti-TB treatment.
Methods: We conducted a retrospective cohort study of all patients with culture-confirmed
pulmonary TB, and identified patients with respiratory cultures positive for NTM during therapy
for pulmonary TB.
Results: From January 2003 to December 2005, 958 patients were diagnosed with culture-
confirmed pulmonary TB. NTM were isolated from 113 specimens in 68 (7.1%) patients during
anti-TB treatment. The most frequently isolated NTM species were Mycobacterium abscessus
(nZ 35, 31%), Mycobacterium fortuitum (nZ 17, 15%), Mycobacterium avium complex
(nZ 9, 8%), and Mycobacterium gordonae (nZ 9, 8%). Forty-eight (71%) patients had only
one positive culture, while 20 (29%) had two or more positive cultures for NTM. Only two
(3%) patients who had two or more positive culture after anti-TB treatment showed the same
NTM species, which were M. abscessus.
Conclusion: The isolation of NTM in patients with pulmonary TB is not uncommon during anti-
TB treatment. However, this is likely the result of colonization, a transient infection, or spec-
imen contamination. The co-existence of pulmonary TB and NTM lung disease may be rare but
should be considered in patients with relatively virulent NTM species such as M. abscessus.
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IV, human immunodeficiency virus; IQR, interquartile range.
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Mycobacteria other than Mycobacterium tuberculosis
complex and Mycobacterium leprae are collectively
referred to as nontuberculous mycobacteria (NTM).1e3
Human disease resulting from NTM infection is classified
into four distinct clinical syndromes: pulmonary disease,
lymphadenitis, cutaneous disease, and disseminated
disease. Among these, chronic pulmonary disease is the
most common localized clinical condition.1e3 Studies have
demonstrated that disease attributable to NTM is on the
rise. NTM are responsible for an increasing proportion of
mycobacterial diseases in many developed and developing
countries.4e8
NTM are ubiquitous organisms and are frequently iso-
lated from environmental sources, including surface
water, tap water, and soil.1,2,9 Accordingly, the isolation
of NTM species from a respiratory sample is insufficient
evidence for the presence of NTM lung disease. Some
patients are infected with NTM without evidence of
pulmonary disease, and such infection may indicate
colonization or transient infection. Therefore, the diag-
nosis of NTM lung disease must rely on clinical, radio-
graphic, and microbiological criteria. The American
Thoracic Society (ATS) issued diagnostic criteria for NTM
lung disease in 1997,1 and the ATS and the Infectious
Diseases Society of America (IDSA) recently revised the
criteria in 2007.2
The guidelines state that the reasonable exclusion of
other etiologies of pulmonary disease is a necessary clinical
criterion, along with the presence of respiratory symptoms,
compatible radiographic abnormalities, and bacteriological
evidence of NTM.2 Furthermore, the guidelines state that
there are clinical problems not directly addressed by the
diagnostic guidelines; one of these is the significance of
NTM isolated from a patient during therapy for pulmonary
tuberculosis (TB).
To date, only a few reports of cases in Japan with
concurrent TB and NTM infections have been published.10e14
However, the frequency and clinical significance of NTM
isolated from patients during treatment for pulmonary TB
are not well studied. Therefore, we investigated the
frequency and clinical significance of NTM isolated from
patients receiving anti-TB treatment.
Patients and methods
Study subjects
We conducted a retrospective cohort study of all patients
with culture-confirmed pulmonary TB who had been diag-
nosed and treated at Samsung Medical Center from January
2003 through December 2005. Samsung Medical Center is
a 1250-bed university-affiliated tertiary referral hospital in
Seoul, South Korea. Among these patients, those with
respiratory cultures positive for NTM during therapy for
pulmonary TB were identified from a computer-assisted
search of medical records. The Institutional Review Board
at Samsung Medical Center approved the study protocol.
Informed consent was waived because of the retrospective
nature of the study.Smears, cultures, and species identification
Generally, the patients with pulmonary TB were treated on
an outpatient basis. Sputum smear and culture examina-
tions were performed monthly for the first 2 months and
then at 1- to 2-month intervals until the end of treatment.
Sputum specimens were collected spontaneously, and
tap water was not any part of the specimen processing.
Clinical specimens were stained using the ZiehleNeelsen
method, according to the ATS guidelines.15 The results of
smear microscopy were reported semi-quantitatively. A
positive smear was defined as one with one or more acid-
fast bacilli (AFB) per 100 high-power fields. Sputum or
bronchial wash specimens were decontaminated using the
N-acetyl-L-cysteine 2% NaOH method, and the processed
specimens were plated on Lo¨wensteineJensen medium.
Inoculated tubes were incubated at 37 C and then
inspected weekly for 8 weeks. To distinguish between
M. tuberculosis and NTM, all AFB isolates were assessed
according to growth rates, colony morphology, and
pigmentation, as well as with a commercial DNA probe
(AMPLICO test; Roche Molecular Systems, Branchburg, NJ).
NTM species were identified using a polymerase chain
reaction and restriction length polymorphism method based
on the rpoB gene, as previously described.6,16,17
Evaluation of clinical and radiographic findings
The medical records of the patients were reviewed, with
respect to the following information: age, gender, smoking
history, underlying pulmonary and non-pulmonary illnesses,
results of anti-human immunodeficiency virus (HIV) anti-
body, AFB smear status, number of positive NTM isolates,
species of NTM organisms, and anti-TB treatment informa-
tion. The extent of radiographic pulmonary TB disease was
graded using the U.S. National Tuberculosis and Respiratory
Disease Association scheme, which classifies disease into
minimal,moderately advanced, and far-advanced disease.18Results
Patients characteristics
From January 2003 to December 2005, 958 patients were
diagnosed with culture-confirmed pulmonary TB. Of these,
68 (7.1%) patients were identified as having positive culture
results for NTM during anti-TB treatment. The median age
of these 68 patients was 52.5 years (interquartile range
[IQR], 35.5e64.0 years). Forty-two (62%) of the patients
were men and 26 were women. Thirty (44%) patients had
never smoked (Table 1).
Twenty-three (34%) patients had a history of pulmonary
TB. Nine (13%) patients had idiopathic pulmonary fibrosis,
and six (9%) had bronchiectasis. Twenty-seven (40%)
patients had underlying non-pulmonary disease, including
diabetes mellitus, malignancies, chronic liver disease, and
chronic kidney disease (Table 1). No patient was seroposi-
tive for antibodies to HIV or belonged to a high-risk group
(i.e. homosexuals, injectable drug users, persons with
hemophilia, or coagulation disorders, etc.).
Table 2 AFB smear and culture findings of specimens with
cultures positive for NTM (nZ 113).
Quantity reported Number (%)
AFB smear
results
No AFB seen 53 (47%)
Doubtful 20 (18%)
Rare (1þ) 17 (15%)
Few (2þ) 11 (10%)
Moderate (3þ) 8 (7%)
Numerous (4þ) 4 (3%)
AFB culture
results
Fewer than 50 colonies 94 (83%)
50e100 colonies 12 (11%)
100e200 colonies 2 (2%)
200e500 colonies
(almost confluence)
4 (3%)
>500 colonies (confluence) 1 (1%)
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(22%) had multidrug-resistant TB, and seven (10%) had any
other drug-resistant TB. The results of drug susceptibility
tests were not available for two patients. Forty-nine (72%)
of the patients had moderately advanced or far-advanced
radiographic disease (Table 1). The duration of the anti-TB
treatment in the 68 patients was a median of 6.6 months
(IQR, 6.0e16.8 months).
Microbiological findings
During anti-TB treatment in the 68 patients, 799 respiratory
specimens were sent to the laboratory for mycobacterial
culture, and 113 specimens were found to be positive for
NTM. The median number of specimens sent for culture per
patient was eight (IQR, 6e16), and the median number of
cultures for NTM per patient was one (IQR, 1e2). The
median interval from starting anti-TB treatment to the first
positive culture for NTM was 2.8 months (IQR, 0.9e5.6
months).
Forty-eight (71%) patients had only one positive culture,
13 (19%) patients had two, and seven (10%) patients had
three or more cultures positive for NTM. Fifty-three (47%)
of the 113 specimen cultures positive culture for NTM were
negative on AFB stain, and 94 (83%) specimen cultures
resulted in fewer than 50 colonies (Table 2).
From the 113 specimens, 114 NTM were isolated and
identified, as two different NTM species were isolated from
one sputum specimen. In nine cases, M. tuberculosis and
NTM were detected from the same sample on sputum
culture. Among the 113 specimens, the most frequently
isolated organisms were Mycobacterium abscessus (nZ 35,Table 1 Patients characteristics (nZ 68).
Variable Value
Age (years) 52.5 (35.5e64)
Male/female 42 (62%)/26 (38%)
Body mass
index (kg/m2)
21.7 (19.6e24.0)
Underlying lung
disease
Previous pulmonary
tuberculosis
23 (34%)
Idiopathic pulmonary
fibrosis
9 (13%)
Bronchiectasis 6 (9%)
Others 6 (9%)
Underlying
medical
disease
Diabetes mellitus 16 (24%)
Malignancy 5 (7%)
Chronic liver disease 3 (4%)
Chronic kidney disease 2 (3%)
Others 5 (7%)
Drug
susceptibility
test
Drug-susceptible TB 44 (65%)
Multidrug-resistant TB 15 (22%)
Other drug-resistant TB 7 (10%)
Not available 2 (3%)
Radiologic
severity
Minimal 19 (28%)
Moderately advanced 39 (57%)
Far advanced 10 (15%)
Data are presented as the median (interquartile range) or
number (%).31%), Mycobacterium fortuitum (nZ 17, 15%), Mycobacte-
rium avium complex (nZ 9, 8%), and Mycobacterium
gordonae (nZ 9, 8%) (Table 3).
Among the 68 patients, the frequently isolated species
were, in decreasing order, M. fortuitum (nZ 14, 21%),
M. abscessus (nZ 13, 19%), M. avium complex (nZ 8, 12%),
and M. gordonae (nZ 8, 12%), Mycobacterium terrae
complex (nZ 3, 4%), and Mycobacterium chelonae (nZ 2,
3%).
Follow-up culture findings
Of the 68 patients, 65 had available follow-up specimens
for AFB culture after the first positive NTM culture results.
Of these 65 patients, 56 converted to negative cultures for
NTM on follow-up sputum cultures during anti-TB treat-
ment. Nine (13%) patients had repeated positive culture
results for NTM after the completion of anti-TB treatment.
The median duration of follow-up after-TB treatment was
23.9 months (IQR, 15.2e32.0 months) in these nineTable 3 Frequency of NTM isolates.
Organisms Isolates
(nZ 114)
Patients
(nZ 68)a
Mycobacterium abscessus 35 (31%) 13 (19%)
Mycobacterium fortuitum 17 (15%) 14 (21%)
Mycobacterium avium complex 9 (8%) 8 (12%)
Mycobacterium intracellulare 3 3
M. avium 6 5
Mycobacterium gordonae 9 (8%) 8 (12%)
Mycobacterium terrae complex 3 (3%) 3 (4%)
Mycobacterium chelonae 3 (3%) 2 (3%)
Mycobacterium septicum 2 (2%) 2 (3%)
Mycobacterium szulgai 1 (1%) 1 (1.5%)
Mycobacterium aubagmense 1 (1%) 1 (1.5%)
Mycobacterium nonchromogenicum 1 (1%) 1 (1.5%)
Unclassified 10 (9%) 10 (15%)
Contamination or loss of isolates 23 (20%) 22 (32%)
a More than one NTM species were isolated from some patient,
so the sum of frequency was over 68.
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last sputum culture, and five patients had positive NTM
culture on the last sputum culture. However, only two (3%)
patients who had two or more positive culture results after
anti-TB treatment grew the same NTM species with those
which were isolated during anti-TB treatment.
The NTM isolated from these two patients who had
persistent positive cultures for NTM during and after anti-
TB treatment was M. abscessus. Despite anti-TB treatment
for culture-confirmed pulmonary TB, these two patients
had respiratory symptoms and compatible radiographic
findings (i.e. cavities or multiple bronchiolitis associated
with bronchiectasis). M. abscessus was isolated more than
five times from these two patients, during and after anti-TB
treatment. Therefore, they could be diagnosed with
M. abscessus lung disease. However, they did not have
demonstrable radiographic progression. So, they were on
the regular follow-up without antibiotic treatment for
M. abscessus lung disease. The duration of follow-up after
anti-TB treatment in these two patients was 32 and 51
months, respectively.Discussion
NTM are ubiquitous environmental organisms. Patients with
pre-existing lung damage are susceptible to NTM. There-
fore, chronic obstructive pulmonary disease, pneumoconi-
osis, previous pulmonary TB, and bronchiectasis are all
associated with NTM lung infection.1,2 According to the
guidelines, the diagnosis of NTM lung disease requires the
exclusion of other disorders such as TB and fungal infec-
tion.1,2 Therefore, the significance of NTM isolated from
a patient with pulmonary TB or pulmonary fungal disease is
uncertain.2 Recently, NTM infection was reported to be
related to Aspergillus-related disease including aspergil-
loma and chronic necrotizing pulmonary aspergillosis.19,20
However, the frequency and clinical significance of NTM
isolated from patients during treatment for pulmonary TB
has not been well studied. Until now, only 10 cases of
concurrent M. tuberculosis and NTM infections have been
reported in Japan.10e14
To our knowledge, this is the largest case series
describing TB patients with cultures positive for NTM during
their anti-TB treatment. We found that 7% of the patients
with culture-confirmed pulmonary TB had positive cultures
for NTM during anti-TB treatment. About two-thirds (44/68,
65%) of our patients had underlying lung disease other than
the diagnosed TB, and 49 (72%) of the patients had
moderately advanced or far-advanced pulmonary TB.
Therefore, the isolation of NTM from patients with pulmo-
nary TB was not uncommon during anti-TB treatment, at
least in our study population.
Given that NTM are ubiquitous in nature, positive
cultures from human airways may indicate infection, colo-
nization, or specimen contamination.21 In our study, 71%
(48/68) of the patients had a single positive culture for NTM
during anti-TB treatment, and only 13% (9/68) had repeated
positive cultures for NTM after completing anti-TB treat-
ment. Moreover, only two (3%) patients had two or more
positive culture results with the same NTM species after
anti-TB treatment.AFB staining of the 113 specimens with cultures positive
for NTM revealed that a large number (nZ 73, 65%) of them
were smear-negative. In addition, the culture results
showed that a large majority of the specimen (nZ 94, 83%)
had fewer than 50 colonies. The clinical relevance of this
finding is not clear, but it indicates that even when
a specimen was positive for NTM, the bacterial burden was
low. Interestingly, the most commonly isolated organism in
our study, on a per-patient basis, was M. fortuitum, which
is a low-virulence NTM.16 In 18% (12/68) of the patients,
NTM species that are usually contaminants, such as
M. gordonae and M. terrae complex were isolated.22
All of these findings suggest that an NTM isolated from
a patient during therapy for pulmonary TB is usually the
result of colonization (i.e., recovery of organisms more
than once without demonstration of specific pulmonary
disease), a transient infection (i.e., transient isolation of
organisms with subsequent negative cultures and no
evidence of disease progression), or specimen contamina-
tion, rather than clinically relevant pulmonary infection.
Therefore, simple follow-up of sputum culture may be
enough at 1- to 2-month intervals until the end of anti-TB
treatment in most patients.
In conclusion, the isolation of NTM from patients with
pulmonary TB is not uncommon during anti-TB treatment.
However, this usually represents colonization, a transient
infection, or specimen contamination. The co-existence of
pulmonary TB and NTM lung disease may be rare, but should
be considered in patients with relatively virulent NTM
species such as M. abscessus.
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